Perinatal lethal hypophosphatasia is a rare inherited condition that affects bone and tooth mineralization before birth or around delivery. Babies with perinatal lethal hypophosphatasia often have very soft or poorly formed bones, a small chest, and severe breathing problems. The early signs of perinatal lethal hypophosphatasia are usually recognized on prenatal ultrasound or at birth, although the exact features can vary. It may help to know that doctors have studied this condition for decades, and treatment now focuses on intensive supportive care and enzyme replacement therapy in selected cases. Even with modern care, perinatal lethal hypophosphatasia is often life-threatening in the newborn period, especially when the lungs cannot develop or work well enough.
How many people live with Perinatal lethal hypophosphatasia?
There are no reliable current counts of how many people are living with perinatal lethal hypophosphatasia worldwide or in the United States, because this very rare form is usually tracked by how often it happens around birth, not by the number of people alive with it. Widely used rare-disease references report that severe hypophosphatasia occurs in about 1 in 100,000 to 1 in 300,000 births in some populations (Orphanet, 2024; GeneReviews, 2020), but they do not provide a dependable current world total or U.S. total for this specific form.
Overview
Perinatal lethal hypophosphatasiaSymptoms
Perinatal lethal hypophosphatasia causes very weak, poorly mineralized bones before birth. Babies often have a soft skull, short limbs, and a small chest that cannot support breathing. Severe breathing failure is common at or soon after birth.
Outlook and prognosis
Perinatal lethal hypophosphatasia is the most severe form and often causes life-threatening breathing problems before or soon after birth. Many affected babies die during pregnancy or in the newborn period. Rare survivors need intensive, ongoing medical support.
Causes and risk factors
Perinatal lethal hypophosphatasia is caused by harmful ALPL gene changes that greatly reduce alkaline phosphatase activity. Most cases are inherited when both parents carry one changed copy; sometimes the change is new. Family history and related-parent pregnancies raise the risk.
Genetic influences
Genetics are central to perinatal lethal hypophosphatasia. It is usually caused by harmful changes in the ALPL gene, and the exact variant often strongly influences how severe the condition is and recurrence risk in a family.
Diagnosis
Diagnosis of perinatal lethal hypophosphatasia often starts before or at birth from clinical features and imaging findings. Doctors look for very low alkaline phosphatase levels. Genetic tests can confirm the genetic diagnosis of perinatal lethal hypophosphatasia.
Treatment and drugs
Perinatal lethal hypophosphatasia needs urgent specialist care from birth. Treatment may include enzyme replacement, breathing support, seizure treatment, and careful management of calcium levels. Care also focuses on comfort and support for families.
Symptoms
Perinatal lethal hypophosphatasia affects bone and lung development before birth, so many babies are very fragile at delivery and need intensive medical care. Early on, this might look like very short limbs, a small chest, or unusually soft bones on prenatal ultrasound. This is the most severe form of hypophosphatasia, and the breathing problems around birth are often life-threatening.
The bones do not harden as they should, so they can look very thin, fragile, or partly formed on scans. Fractures and marked bending of the arms, legs, or ribs can happen because the skeleton is so weak.
The arms and legs are often much shorter than expected and may look bowed or misshapen. These are among the early features of perinatal lethal hypophosphatasia that doctors may notice before birth.
The rib cage is usually narrow and underdeveloped, which leaves less room for the lungs to grow. In perinatal lethal hypophosphatasia, this small chest is a major reason breathing is so difficult at birth.
The skull bones may be very soft, with wide gaps between them and less firmness than usual. Sometimes the head looks larger or changes shape because the skull has not mineralized well.
How people usually first notice Perinatal lethal hypophosphatasia?
Perinatal lethal hypophosphatasia is usually first noticed before birth or right at delivery, often when prenatal ultrasound shows bones that look poorly mineralized, very short or bowed arms and legs, a soft skull, or a chest that seems too small. After birth, the first signs of perinatal lethal hypophosphatasia are often severe breathing trouble because the ribs and chest have not developed enough to support normal lung expansion, along with fragile bones and sometimes seizures linked to very low vitamin B6 activity in the brain. For families, how perinatal lethal hypophosphatasia is first noticed is usually through these striking early findings rather than subtle symptoms, which is why diagnosis often begins with urgent newborn care and imaging.
Types of Perinatal lethal hypophosphatasia
No distinct types of perinatal lethal hypophosphatasia are widely recognized.
Can I slow down the onset of symptoms?
No. For perinatal lethal hypophosphatasia, a rare inherited condition that causes very severe bone problems before birth or at birth, there is no good evidence that lifestyle changes like diet, exercise, sleep, or supplements can delay when symptoms begin. Because this form starts so early, lowering risk is not the same as preventing it, and care focuses instead on early diagnosis, close monitoring in pregnancies at risk, and specialist treatment after birth; a treatment that replaces the missing body chemical needed for bone building may help some babies survive longer, but it does not stop the condition from starting. If this condition may run in your family, early support from a genetics team and a high-risk pregnancy team can still help you understand your options and plan care, even though it cannot guarantee a different outcome.
What genetics can tell you about symptoms
In perinatal lethal hypophosphatasia, changes in the ALPL gene are the direct cause of the condition, and they usually lead to very low activity of an enzyme needed to build and maintain hard, healthy bones. Genetics can help explain why symptoms begin before birth or at delivery and why they are so severe, including very soft or poorly mineralized bones, a small chest, breathing problems, and sometimes seizures related to low vitamin B6 activity. The exact course can still vary somewhat from one baby to another, but in this form of hypophosphatasia, the gene changes are strongly linked to an early start and life-threatening symptoms.
Causes and risk factors
Perinatal lethal hypophosphatasia is caused by a harmful change in the ALPL gene. This change leads to very low levels of alkaline phosphatase, an enzyme needed for bones to harden normally before birth. It is often inherited when both parents carry a changed copy of ALPL, but a new gene change can also happen for the first time in a family. Family history or a previous affected pregnancy raises the risk of perinatal lethal hypophosphatasia, while lifestyle, diet, and routine pregnancy exposures are not known to be primary causes. Knowing your family history is a good first step, and genetic testing can sometimes clarify the risk in future pregnancies.
What are the most common causes or risk factors?
Perinatal lethal hypophosphatasia is almost always caused by harmful changes in a gene called ALPL, which leads to very low levels of alkaline phosphatase, a body chemical needed to build strong bones before birth. The main risk factor is family history, especially when both biological parents carry one changed copy of this gene and pass both changed copies to the baby; the chance can also be higher if the parents are blood relatives. There are no well-known lifestyle, diet, or environmental causes for this condition.
Environmental and biological risk factors
For perinatal lethal hypophosphatasia, no well-established environmental or non-genetic biological risk factors have been identified. Doctors often group risks into internal (biological) and external (environmental). In practice, common pregnancy exposures and most maternal health issues have not been shown to clearly increase the chance of this condition.
No common environmental exposure has been clearly proven to cause this condition. This includes concerns such as radiation, heavy metals, air pollution, or industrial chemicals, where a direct link has not been established.
Common health conditions during pregnancy, such as diabetes, high blood pressure, or thyroid disease, are not known to specifically raise the likelihood. Researchers have not identified a separate non-genetic maternal factor that reliably predicts it.
Unlike some chromosomal conditions, older maternal or paternal age is not a known major risk factor for perinatal lethal hypophosphatasia. Current evidence does not show that age alone clearly raises the chance.
No routine medicine, vaccine, or common pregnancy infection has been consistently linked to perinatal lethal hypophosphatasia. Current evidence does not support a clear causal connection.
Genetic risk factors
Perinatal lethal hypophosphatasia is almost always linked to changes in a gene called ALPL, which helps the body build and mineralize bones and teeth. When this gene is not working well, a baby can develop very weak bones before birth, sometimes severe enough to affect the chest and breathing. In most families, the genetic causes of perinatal lethal hypophosphatasia involve one altered copy of ALPL inherited from each parent. Carrying a genetic change doesn’t guarantee the condition will appear, because the risk depends on how many altered copies are present and which variants are involved.
ALPL changes: The main genetic cause of perinatal lethal hypophosphatasia is harmful changes in the ALPL gene. This gene makes an enzyme needed for normal bone hardening, so major loss of its function can lead to severe skeletal problems before birth.
Recessive inheritance: This severe form is usually inherited in an autosomal recessive pattern, meaning a baby receives two altered ALPL copies, one from each parent. When both copies are significantly affected, the disease is more likely to be very severe.
Carrier parents: Many parents of an affected baby are healthy carriers, with one working copy of ALPL and one altered copy. If both parents are carriers, each pregnancy has a 25% chance of perinatal lethal hypophosphatasia, a 50% chance of carrier status, and a 25% chance of inheriting no altered copy.
Family history: A previous affected pregnancy or a close relative with hypophosphatasia can raise the chance that the same ALPL changes are present in a family. People with the same risk factor can have very different experiences, because the condition can range from very severe to much milder forms depending on the variants involved.
Related parents: The genetic risk is higher when parents are biologically related, such as cousins, because they are more likely to carry the same rare ALPL change. This does not cause the condition by itself, but it increases the chance that a baby inherits two altered copies.
New variants: In rare cases, a new change in ALPL can arise for the first time in a baby instead of being passed down through a family. This is less common than inheriting the condition from two carrier parents.
Lifestyle risk factors
Lifestyle habits do not cause perinatal lethal hypophosphatasia, but daily care decisions can still affect comfort, complications, and survival in babies who receive intensive treatment. In this condition, how lifestyle affects perinatal lethal hypophosphatasia is mainly about pregnancy health, newborn support, and careful coordination with specialist care. Because the disorder is so severe, even basic issues such as feeding, positioning, and infection prevention can have direct effects on breathing, bone fragility, and overall stability.
During an affected pregnancy, avoiding alcohol, smoking, and non-prescribed drugs may help reduce extra stress on fetal growth and breathing. These habits do not cause the condition, but they can worsen the overall health challenges around delivery and neonatal care.
Good maternal nutrition and appropriate prenatal vitamin use support the best possible background for fetal growth. They do not correct the bone mineralization problem in perinatal lethal hypophosphatasia, but poor nutrition can add to weakness and medical instability.
Careful feeding plans can lower the risk of choking, poor weight gain, and aspiration in fragile newborns. For babies who cannot feed safely by mouth, following specialist guidance on tube feeding can directly affect strength, breathing, and tolerance of treatment.
Gentle handling and supportive positioning are important because the bones and chest can be extremely fragile. Rough transfers or poor positioning may increase pain, fracture risk, and breathing difficulty.
Risk prevention
Perinatal lethal hypophosphatasia is a rare inherited condition, so there is usually no way to prevent the condition itself once a pregnancy is affected. Prevention mainly means lowering the chance of an affected pregnancy through genetic testing and family planning, and using early specialist care to reduce complications when the condition is suspected. Different people need different prevention strategies—there’s no single formula.
If perinatal lethal hypophosphatasia has happened in your family, meeting with a genetics specialist before pregnancy can clarify the chance of it happening again. This can help families understand inheritance, testing choices, and what prevention is realistically possible.
Testing the ALPL gene in parents or relatives can show whether they carry the changed gene linked to perinatal lethal hypophosphatasia. Knowing this before pregnancy can guide reproductive decisions and help identify risk early.
Some families choose options such as IVF with embryo testing or the use of donor egg or sperm to lower the chance of another affected pregnancy. Knowing your risks can guide which preventive steps matter most.
During pregnancy, targeted genetic testing and detailed ultrasound can sometimes detect early signs of perinatal lethal hypophosphatasia. While this does not prevent the condition, it can help with planning for delivery, newborn care, and discussions about what to expect.
Can you prevent Perinatal lethal hypophosphatasia?
No, perinatal lethal hypophosphatasia usually cannot be prevented because it is caused by inherited changes in a gene, and those changes affect bone growth before birth. If it runs in your family, meeting with a genetics specialist before pregnancy can help you understand the risk and discuss options such as family testing or testing during fertility treatment, but these steps may lower the chance of it happening again rather than fully prevent it.
Transmission
Perinatal lethal hypophosphatasia is not infectious, so it cannot be caught from someone or spread through the air, food, blood, or everyday contact. Instead, it is a genetic condition that is present before birth.
In most families, how perinatal lethal hypophosphatasia is inherited means a baby receives a changed ALPL gene from both parents, who are usually healthy carriers. With each pregnancy, two carrier parents have a 1 in 4, or 25%, chance of having a child with perinatal lethal hypophosphatasia, a 1 in 2, or 50%, chance of having a child who is also a carrier, and a 1 in 4, or 25%, chance of having a child who has neither changed copy. Rarely, the condition can happen because of a new gene change in the baby.
When to test your genes
Genetic testing is most useful before or during pregnancy if there is a family history, known parental carrier status, or a prior affected pregnancy. It is also considered when prenatal ultrasound shows severely under-mineralized bones, a small chest, or very short limbs. Confirming ALPL variants helps clarify the diagnosis and recurrence risk.
Diagnosis
Perinatal lethal hypophosphatasia is usually suspected when a baby shows severe bone changes before birth or at delivery, such as very soft or underdeveloped bones and a small chest that can make breathing difficult. Getting a diagnosis is often a turning point toward answers and support. The genetic diagnosis of Perinatal lethal hypophosphatasia is then confirmed with lab testing and genetic tests, while doctors also rule out other rare bone conditions that can look similar.
Doctors may first suspect Perinatal lethal hypophosphatasia during pregnancy when ultrasound shows poor bone mineralization, shortened or bowed limbs, or a chest that appears unusually small. These imaging findings can raise concern early, although they are not unique to this condition.
After birth, doctors look for clinical features such as very soft bones, a small chest, and signs of severe breathing problems. These findings help show how strongly the skeleton has been affected and guide urgent care.
X-rays often show bones that are poorly mineralized, fragile, or unusually shaped, with some areas appearing almost absent. This pattern helps support the diagnosis of Perinatal lethal hypophosphatasia and distinguish it from other skeletal disorders.
Blood tests usually show very low alkaline phosphatase, an enzyme that is typically low in hypophosphatasia rather than high as in many other bone problems. Other lab tests may also show raised substances normally broken down by this enzyme, which strengthens the diagnosis.
How is Perinatal lethal hypophosphatasia diagnosed?
Perinatal lethal hypophosphatasia is usually suspected during pregnancy or right after birth when scans or X-rays show that the bones have not hardened properly and the chest, arms, or legs look very underdeveloped. Doctors then use a blood test to look for very low levels of alkaline phosphatase, an enzyme the body needs for normal bone growth, along with the baby’s symptoms and exam findings. A genetic test can help confirm the diagnosis by finding a change in the ALPL gene, but it is usually used alongside the scan, X-ray, and blood test results rather than on its own.
Stages of Perinatal lethal hypophosphatasia
Perinatal lethal hypophosphatasia does not have defined progression stages. This is because it is a very severe form that is usually recognized before birth or around delivery, rather than slowly moving through clear steps over time. Doctors usually start with a conversation about pregnancy findings and symptoms, then use ultrasound, X-rays after birth, blood tests showing very low alkaline phosphatase, and often genetic testing to confirm the diagnosis. In many families, the early symptoms of perinatal lethal hypophosphatasia are first seen on prenatal scans, and follow-up focuses on confirming the cause and guiding care decisions.
Outlook and prognosis
The outlook for perinatal lethal hypophosphatasia is extremely poor, with many affected fetuses dying before birth or newborns dying within hours to days from severe respiratory failure caused by profound skeletal underdevelopment and a poorly mineralized chest. Historically, mortality in the untreated perinatal lethal form has been very high, and this remains one of the most severe presentations of hypophosphatasia. Survival has improved in some infants with early intensive supportive care and enzyme replacement therapy with asfotase alfa, but outcomes still vary and are generally guarded. Babies who survive the newborn period often face major medical complications, including respiratory dependence, fractures, seizures related to vitamin B6-responsive epilepsy, feeding difficulties, and severe growth problems. Even with treatment, long-term prognosis depends on how early therapy begins, how severe the bone and lung disease is at birth, and whether complications can be controlled. Families should be counseled that perinatal lethal hypophosphatasia carries a substantial risk of early death, although newer treatment has created meaningful survival in a subset of affected infants.
Long-term effects
Perinatal lethal hypophosphatasia has a very serious outlook, and most affected babies die before birth or in the first days to weeks of life. For the small number who survive with intensive medical support, the long-term picture usually involves major ongoing health problems rather than a typical childhood course. Everyone’s path looks different, and ongoing support is especially important because outcomes can vary with access to breathing support and newer treatments.
Perinatal lethal hypophosphatasia most often leads to death before delivery or shortly after birth because the lungs and chest do not develop well enough to support breathing. This is the main reason the condition is called lethal.
Babies who survive often have severe long-term breathing trouble and may need prolonged ventilation or other respiratory support. A small chest, weak ribs, and fragile bones can make normal breathing difficult over time.
In survivors, bones may remain very soft, fragile, and poorly mineralized, leading to repeated fractures, chest wall problems, and poor growth. Some of the early symptoms of perinatal lethal hypophosphatasia that continue over time are tied to how weak the skeleton remains.
Survivors can develop seizures, pressure on the brain from skull changes, and complications linked to high calcium levels in the blood. These problems may affect feeding, development, comfort, and overall survival in infancy and early childhood.
How is it to live with Perinatal lethal hypophosphatasia?
Perinatal lethal hypophosphatasia is the most severe form of hypophosphatasia, and many affected babies become critically ill before or shortly after birth because their bones, chest, and lungs do not develop enough to support breathing and survival. For families, this usually means a pregnancy or newborn period filled with intensive monitoring, difficult medical decisions, and often profound grief, rather than the long-term day-to-day adjustments seen in milder conditions. The effects reach far beyond the baby, often placing major emotional strain on parents, siblings, and loved ones, who may need ongoing medical, bereavement, and genetic counseling support.
Treatment and drugs
Perinatal lethal hypophosphatasia is treated as a medical emergency from birth, with care focused on helping a baby breathe, feed, and stay as comfortable and stable as possible while a specialist team watches for problems such as weak bones, chest changes, and low oxygen levels. In many babies, treatment also includes enzyme replacement therapy to replace the missing enzyme that the body cannot make enough of, and this can improve survival and bone mineralization in some severe forms of hypophosphatasia. Treatment plans often combine several approaches, including breathing support, careful nutrition, pain relief, and close monitoring in a neonatal intensive care unit, with genetics and bone specialists guiding longer-term decisions. Because this condition is extremely severe, families usually need frequent updates about what treatment may realistically achieve, and care may range from intensive life-support measures to comfort-focused care depending on how sick the baby is and whether treatment is helping.
Can you cure Perinatal lethal hypophosphatasia?
No, there is not currently a cure for perinatal lethal hypophosphatasia. Treatment cannot fully take the condition away, but it may help some babies by replacing the missing substance their body needs to build stronger bones and by supporting breathing, feeding, and comfort. Because this form is very severe and outcomes can vary, care is usually led by a team with experience in high-risk newborns and rare bone conditions.
Non-drug treatment
Perinatal lethal hypophosphatasia can cause life-threatening breathing problems, very weak bones, and major feeding and comfort needs from the time before birth or shortly after delivery. Care is centered on keeping the baby as stable and comfortable as possible, supporting the family, and planning treatment with a specialist team. Managing this condition often means using intensive supportive care in the hospital, and in some cases focusing on comfort care if survival is not possible.
Weak ribs and a soft chest can make it hard for a newborn with perinatal lethal hypophosphatasia to breathe on their own. Care may include oxygen, gentle ventilation, or a breathing machine in a neonatal intensive care unit.
Many babies cannot feed safely or take in enough calories because they are very weak or working hard to breathe. Tube feeding and close nutrition support can help protect energy, growth, and comfort.
Pain control, careful positioning, and gentle handling are important because fragile bones can hurt and break easily. Supportive therapies can also ease distress, reduce unnecessary procedures, and help families make care choices that match their goals.
Soft bedding, splints when needed, and careful movement can help lower the risk of fractures and improve comfort. If a baby lives beyond the newborn period, physical and occupational therapy may help with positioning, joint movement, and day-to-day care.
Your genes may have an impact on how drugs work for you
For families facing perinatal lethal hypophosphatasia, the main day-to-day issue is that this condition is caused by a change in a gene that affects how bones and lungs develop, and that same change often shapes how severe the illness is and whether enzyme replacement treatment may help. Unlike some other conditions, there are no well-established examples showing that common medicines work differently in these babies because of separate drug-response gene changes, so genetic testing is used mostly to confirm the diagnosis and guide care rather than to match a child to one drug over another. Because this form is very severe and can vary from baby to baby, treatment decisions are usually based on the baby’s symptoms, breathing, bone problems, and overall condition, together with the genetic results.
Pharmacological treatments
For families facing perinatal lethal hypophosphatasia, treatment usually centers on medicines that support breathing, bone mineralization, and seizure control in the earliest days of life. The main drug is asfotase alfa, an enzyme replacement that can improve survival and help bones mineralize more normally. Medication can feel like a big step, but early treatment for perinatal lethal hypophosphatasia has changed the outlook for some babies. Some newborns also need pyridoxine if vitamin B6-responsive seizures occur.
Asfotase alfa is the standard disease-targeting treatment for perinatal lethal hypophosphatasia because it replaces the missing alkaline phosphatase enzyme. It is given by injection and may improve bone mineralization, breathing, and overall survival, although response can vary from baby to baby. Doctors usually start it as early as possible and monitor growth, breathing, calcium levels, and bone changes closely.
Pyridoxine, a form of vitamin B6, may be used when perinatal lethal hypophosphatasia causes seizures in the newborn period. It does not treat the underlying bone disease, but it can help control this specific complication. If seizures are present, the care team may also use standard anti-seizure medicines if needed.
Genetic influences
For families facing perinatal lethal hypophosphatasia, the question of why this happened often leads back to genetics. It’s natural to ask whether family history plays a role. This form of hypophosphatasia is caused by harmful changes in the ALPL gene, which makes an enzyme the body needs for bones to harden properly before birth. In most cases, a baby is affected only when they inherit a nonworking copy of ALPL from each parent, which means the condition usually follows an autosomal recessive pattern. Because parents who carry one changed copy are often healthy, there may be no warning signs in the family history, even though each pregnancy has a 1 in 4, or 25%, chance of being affected. Understanding the genetic causes of perinatal lethal hypophosphatasia can help families decide about genetic testing, counseling, and planning for future pregnancies.
Is Perinatal lethal hypophosphatasia genetic?
Genetics are central to perinatal lethal hypophosphatasia. It is usually caused by harmful changes in the ALPL gene, and the exact variant often strongly influences how severe the condition is and recurrence risk in a family.
Having a genetic risk is not necessarily a diagnosis
Gene variants are a normal and common part of human biology. Most of these variants do not directly affect health and are simply one part of natural human diversity. For many genes, having a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when more than one gene and environmental factors are involved. In some cases, though, a single well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
When a baby has very soft bones and trouble breathing around birth, the exact gene change can help guide treatment quickly. In perinatal lethal hypophosphatasia, genetic testing confirms changes in the ALPL gene, which affects the body’s ability to make enough alkaline phosphatase, an enzyme needed for normal bone and tooth mineralization. That matters because the main targeted treatment, enzyme replacement with asfotase alfa, works by replacing the missing enzyme, and starting care early can be especially important. Not every difference in response is genetic, but in perinatal lethal hypophosphatasia the specific ALPL changes can give doctors a clearer sense of how severe the condition may be and how closely a baby may need support for breathing, feeding, and bone health. Some babies have almost no remaining enzyme activity, while others have a little, and that can affect how much improvement is seen with treatment. Early genetic testing for perinatal lethal hypophosphatasia also helps families understand the chance of the condition happening again in a future pregnancy and may guide testing for relatives.
Interactions with other conditions
Perinatal lethal hypophosphatasia often affects more than the bones alone, and for many families the most serious problems involve breathing, feeding, and overall stability right after birth. This severe form can overlap in appearance with other bone disorders seen in newborns, especially conditions that also cause very soft, poorly mineralized bones, so doctors usually need imaging and lab tests to sort out the cause. Some babies with perinatal lethal hypophosphatasia also develop seizures related to low activity of the enzyme involved in vitamin B6 handling, and severe chest weakness can make lung problems much harder to manage. Doctors call it a comorbidity when two conditions occur together. Because this condition can also be linked with high calcium levels and kidney complications, the medical team usually watches several organ systems at once rather than focusing only on the skeleton.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Perinatal lethal hypophosphatasia?
Other conditions that can look similar include severe osteogenesis imperfecta, often called brittle bone disease, and other rare bone growth conditions such as thanatophoric dysplasia and achondrogenesis, which can also cause very soft or poorly formed bones, short limbs, and a small chest before birth or at birth. In some babies, severe forms of rickets or other problems that keep bones from hardening normally may also be considered.
History
Long before modern testing existed, doctors and families recognized that some babies developed unusually soft, poorly mineralized bones before birth or soon after delivery and became critically ill very early in life. These severe cases were described in medical reports over many decades, often through findings on pregnancy scans, X-rays, and examination after birth, as physicians tried to understand why bone and chest development had not progressed in the usual way.
As medical science evolved, these observations were linked to a group of conditions now known as hypophosphatasia. Perinatal lethal hypophosphatasia came to describe the most severe form, seen during pregnancy or around the time of birth. Early descriptions focused on what doctors could see, such as very short or fragile bones, a small chest, and poor mineral buildup in the skeleton. For many families, this history helps explain why older medical records may use different terms or describe the condition in slightly different ways.
Later, better imaging during pregnancy made it easier to recognize the early symptoms of perinatal lethal hypophosphatasia before birth. A scan might show bones that appear less dense than expected or a chest that has not grown enough to support breathing after delivery. Researchers then connected these visible features with changes in the body’s bone-mineral process, and later still identified a genetic cause. That shift mattered because it helped separate perinatal lethal hypophosphatasia from other serious skeletal conditions that can look similar on prenatal scans.
In recent years, diagnosis has become more precise, and doctors can often combine ultrasound findings, family history, blood tests, and genetic testing to confirm what is going on. Even so, the history of perinatal lethal hypophosphatasia is also a story of changing language and improving understanding. What once seemed like a single unexplained bone disorder is now recognized as a distinct, very severe form within a broader condition, which has helped families get clearer answers, counseling, and support.